Archive | Enrolled Participants News RSS feed for this section

2018 PPMI Annual Meeting Summary

The 2018 PPMI Annual Investigator’s Meeting took place on May 2-3 in New York City.  There were more than 200 attendees present, including PPMI investigators and coordinators, Industry Scientific Advisory Board representatives, The Edmond J. Safra Fellowship in Movement Disorders fellows and fellowship directors, the PPMI Patient Committee, and the PPMI Steering Committee. This meeting […]

Continue reading...

Collaboration with Verily Aims to Deepen Parkinson’s Understanding through Digital Health Tools

Wearable sensors to monitor health-related measures like heart rate, glucose levels, or physical activity are helping people assess their own health and enabling research in treating and understanding chronic disease. The Michael J. Fox Foundation (MJFF) and Verily Life Sciences LLC, an Alphabet company, are collaborating to use wearable devices — in conjunction with clinic-based data and […]

Continue reading...

PPMI Steering Committee Paper Accepted to Movement Disorders Journal

We are excited to announce a recent research article using longitudinal data from PPMI has been accepted to Movement Disorders.  Members of the PPMI Steering Committee, including Dr. Tanya Simuni of Northwestern University, authored this publication on behalf of PPMI. The study, entitled “Longitudinal Change of Clinical and Biological Measures in Early Parkinson’s Disease: Parkinson’s […]

Continue reading...

PPMI Study Update Call – 3/15/18

PPMI Study Update Call Thursday, March 15 12-1 pm Eastern Time Andrew Siderowf, MD, MSCE Professor of Neurology University of Pennsylvania Co-Principal Investigator of PPMI   PPMI participants are encouraged to call in to the next quarterly Study Update Call on Thursday, March 15, 2018 at 12 pm EST.  During this call, Dr. Andrew Siderowf, […]

Continue reading...

The Michael J. Fox Foundation Announces $25,000 PPMI Data Challenge to Advance Parkinson?s Understanding and Study Design

Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson?s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: ? What factors at baseline predict […]

Continue reading...

2016 PPMI Annual Meeting held in New York City

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]

Continue reading...

PPMI Q1 2016 Study Update call

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.

Continue reading...

Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Many patients with Parkinson?s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson?s Disease indicates that lower concentrations of ?-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.

Continue reading...

Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid ?-synuclein species as surrogate biomarkers for Parkinson?s disease

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF ?-synuclein species as surrogate biomarkers for Parkinson?s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]

Continue reading...

Dr. Martin Rabey to use PPMI biospecimens for validation of a blood based gene expression assay

A critical component of PPMI is the standardized, longitudinal collection of biospecimens. Each month the Biospecimen Review Committee examines requests for biospecimens collected through the PPMI study. We are excited to announce approval for Dr. Martin Rabey, the Chief Medical Officer of BioShai Ltd, for a project entitled: Validation of a blood based gene expression […]

Continue reading...